甲胺及其纳米配方在癌症预防和治疗中的作用
Biswajit Banerjee1, Sabyasachi Banerjee2, Tripti Sharma1,3
1Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, 751003, Odisha, India.
Current pharmaceutical design
|April 10, 2025
概括
甲福明是一种抗糖尿病药物,通过促进亡,显示出显著的抗癌活性. 甲胺纳米配方增强了这种效果,为癌症治疗提供了一个有前途的策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 纳米技术 纳米技术
背景情况:
- 耐药性是癌症治疗的一个主要挑战.
- 甲胺是一种常见的2型糖尿病药物,具有抗癌性质.
- 改进的药物输送系统对于提高癌症治疗疗效至关重要.
研究的目的:
- 审查甲胺对抗各种癌症的分子机制.
- 讨论用于癌症治疗的甲胺纳米配方的进展.
- 评估甲胺纳米配方的可行性,局限性和挑战性.
主要方法:
- 在电子数据库 (Scopus,Google Scholar,PubMed,Medline,Science Direct) 中进行全面的文献搜索.
- 汇编和分析以前报告的关于甲福明抗癌性质和纳米配方的研究.
- 审查研究甲福明的分子通路和纳米配方疗效的研究.
主要成果:
- 甲素通过诱导细胞死亡,主要是细胞亡,有效地对抗癌症.
- 甲胺及其纳米配方对各种癌细胞系具有显著的抗癌活性.
- 与自由甲胺相比,含有甲胺的纳米配方表现出更高的抗瘤活性.
结论:
- 甲胺具有显著的抗癌特性,得到了广泛研究的支持.
- 甲胺纳米配方为癌症管理提供了增强的治疗疗效.
- 含有甲胺的纳米配方是癌症治疗的潜在有价值的选择.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
142
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
142
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Prevention
6.0K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.0K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Oral Hypoglycemic Agents: Glinides
112
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
112


